Observation for Clinically Localized Prostate CancerNELSON, Joel B.Journal of clinical oncology. 2014, Vol 32, Num 13, pp 1295-1298, issn 0732-183X, 4 p.Article

Debate : Open radical prostatectomy vs. laparoscopic vs. roboticNELSON, Joel B.Urologic oncology. 2007, Vol 25, Num 6, pp 490-493, issn 1078-1439, 4 p.Conference Paper

Prostate cancer: radical prostatectomyNELSON, Joel B; LEPOR, Herbert.Urologic clinics of North America. 2003, Vol 30, Num 4, issn 0094-0143, viii, 703-723 [22 p.]Article

Multimodal analgesic approach incorporating paravertebral blocks for open radical retropubic prostatectomy: a randomized double-blind placebo-controlled studyCHELLY, Jacques E; PLOSKANYCH, Taras; FENG DAI et al.Canadian journal of anaesthesia. 2011, Vol 58, Num 4, pp 371-378, issn 0832-610X, 8 p.Article

Delayed intraoperative hydration limits blood loss during radical retropubic prostatectomyDAVIES, Benjamin J; CHUNG, Steve Y; NELSON, Joel B et al.Urology (Ridgewood, NJ). 2004, Vol 64, Num 4, pp 712-716, issn 0090-4295, 5 p.Article

Comparative Hospital Cost-analysis of Open and Robotic-assisted Radical ProstatectomyTOMASZEWSKI, Jeffrey J; MATCHETT, Jarred C; DAVIES, Benjamin J et al.Urology (Ridgewood, NJ). 2012, Vol 80, Num 1, pp 126-129, issn 0090-4295, 4 p.Article

Phase 3, Randomized, Placebo-Controlled Study of Zibotentan (ZD4054) in Patients With Castration-Resistant Prostate Cancer Metastatic to BoneNELSON, Joel B; FIZAZI, Karim; MILLER, Kurt et al.Cancer. 2012, Vol 118, Num 22, pp 5709-5718, issn 0008-543X, 10 p.Article

Intraoperative cell salvage in radical prostatectomy does not appear to increase long-term biochemical recurrence, metastases, or mortalityRAVAL, Jay S; NELSON, Joel B; WOLDEMICHAEL, Elen et al.Transfusion (Philadelphia, PA). 2012, Vol 52, Num 12, pp 2590-2593, issn 0041-1132, 4 p.Article

Prolongation of Off-Cycle Interval by Finasteride Is Not Associated With Survival Improvement in Intermittent Androgen DeprivationTherapy in LNCaP Tumor ModelYUJUAN WANG; GUPTA, Shubham; VI HUA et al.The Prostate. 2010, Vol 70, Num 2, pp 147-154, issn 0270-4137, 8 p.Article

Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate CancerNELSON, Joel B; LOVE, William; CHIN, Joseph L et al.Cancer. 2008, Vol 113, Num 9, pp 2478-2487, issn 0008-543X, 10 p.Article

Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable - derived cancer chemopreventive agent, is mediated by Bak and BaxDONG XIAO; YAN ZENG; SUNGA CHOI et al.Clinical cancer research. 2005, Vol 11, Num 7, pp 2670-2679, issn 1078-0432, 10 p.Article

Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loopsGURULI, Georgi; PFLUG, Beth R; PECHER, Stefana et al.Blood. 2004, Vol 104, Num 7, pp 2107-2115, issn 0006-4971, 9 p.Article

Nonandrogenic mediators of prostatic growthKONETY, Badrinath R; NELSON, Joel B.Hematology/oncology clinics of North America. 2001, Vol 15, Num 3, issn 0889-8588, vi, 459-476 [19 p.]Article

Contemporary Grading for Prostate Cancer: Implications for Patient CareBRIMO, Fadi; MONTIRONI, Rodolfo; EGEVAD, Lars et al.European urology. 2013, Vol 63, Num 5, pp 892-901, issn 0302-2838, 10 p.Article

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate CancerFIZAZI, Karim S; HIGANO, Celestia S; NELSON, Joel B et al.Journal of clinical oncology. 2013, Vol 31, Num 14, pp 1740-1747, issn 0732-183X, 8 p.Article

Inhibition of 5α -Reductase Enhances Testosterone-Induced Expression of U19/Eaf2 Tumor Suppressor During the Regrowth of LNCaPXenograft Tumor in Nude MiceGUPTA, Shubham; YUJUAN WANG; RAMOS-GARCIA, Raquel et al.The Prostate. 2010, Vol 70, Num 14, pp 1575-1585, issn 0270-4137, 11 p.Article

Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation TherapyGREENSPAN, Susan L; NELSON, Joel B; TRUMP, Donald L et al.Journal of clinical oncology. 2008, Vol 26, Num 27, pp 4426-4434, issn 0732-183X, 9 p.Article

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancerGREENSPAN, Susan L; COATES, Penelope; SEREIKA, Susan M et al.The Journal of clinical endocrinology and metabolism. 2005, Vol 90, Num 12, pp 6410-6417, issn 0021-972X, 8 p.Article

The impact of patient advocacy: The University of California-San Francisco experience. DiscussionCARROLL, Peter R; NELSON, Joel B.The Journal of urology. 2004, Vol 172, Num 5, pp S58-S62, issn 0022-5347, 2Conference Paper

Using molecular markers to predict outcome. DiscussionRUBIN, Mark A; KANTOFF, Philip W; ROSEN, Neal et al.The Journal of urology. 2004, Vol 172, Num 5, pp S18-S22, issn 0022-5347, 2Conference Paper

Costs of Radical Prostatectomy for Prostate Cancer: A Systematic ReviewBOLENZ, Christian; FREEDLAND, Stephen J; HOLLENBECK, Brent K et al.European urology. 2014, Vol 65, Num 2, pp 316-324, issn 0302-2838, 9 p.Article

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy : A multi-institutional pilot studyKIBEL, Adam S; ROSENBAUM, Eli; COOKSON, Michael S et al.The Journal of urology. 2007, Vol 177, Num 5, pp 1777-1781, issn 0022-5347, 5 p.Article

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : A randomized trialGREENSPAN, Susan L; NELSON, Joel B; TRUMP, Donald L et al.Annals of internal medicine. 2007, Vol 146, Num 6, pp 416-424, issn 0003-4819, 9 p.Article

Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tractSTEIN, Robert J; SANTOS, Soledad; CHANCELLOR, Michael B et al.The Journal of urology. 2004, Vol 172, Num 3, pp 1175-1178, issn 0022-5347, 4 p.Article

Page / 3